利拉鲁肽治疗青少年肥胖的随机对照试验
这项随机双盲试验纳入12至<18岁肥胖且单用生活方式治疗效果不佳的青少年,比较每日皮下注射利拉鲁肽3.0 mg与安慰剂(均联合生活方式治疗)对56周BMI标准差评分变化的影响。结果显示利拉鲁肽组BMI标准差评分降幅显著大于安慰剂组(估计差值-0.22,95%CI -0.37至-0.08,P=0.002),但胃肠道不良事件和因不良事件停药更多,停药后BMI标准差评分反弹更明显。
要点
- 利拉鲁肽3.0 mg联合生活方式治疗可显著降低青少年肥胖患者56周BMI标准差评分。
- 利拉鲁肽组BMI降低≥5%和≥10%的比例均高于安慰剂组。
- 利拉鲁肽组胃肠道不良事件及因不良事件停药比例更高,停药后BMI标准差评分反弹更明显。
核心结论
- 在肥胖青少年中,利拉鲁肽3.0 mg联合生活方式治疗比安慰剂联合生活方式治疗显著更大程度降低56周BMI标准差评分。
研究设计与样本
- 随机、双盲试验,包括56周治疗期和26周随访期,纳入12至<18岁肥胖且单用生活方式治疗效果不佳的青少年。
- 参与者按1:1随机分配至利拉鲁肽3.0 mg或安慰剂皮下注射每日一次,均联合生活方式治疗。
- 利拉鲁肽组125例,安慰剂组126例。
- 主要终点为第56周BMI标准差评分相对基线的变化。
主要发现
- 第56周BMI标准差评分相对基线变化,利拉鲁肽优于安慰剂(估计差值-0.22;95%CI -0.37至-0.08;P=0.002)。
- BMI降低至少5%者:利拉鲁肽组51/113例,安慰剂组20/105例(估计百分比43.3% vs. 18.7%)。
- BMI降低至少10%者:利拉鲁肽组33例,安慰剂组9例(估计百分比26.1% vs. 8.1%)。
- BMI估计差值-4.64个百分点;体重绝对变化估计差值-4.50 kg,相对变化估计差值-5.01个百分点,均支持利拉鲁肽更优。
- 停药后BMI标准差评分增加,利拉鲁肽大于安慰剂(估计差值0.15;95%CI 0.07至0.23)。
关键数值与推荐
- 利拉鲁肽组胃肠道不良事件81/125例(64.8%),安慰剂组46/126例(36.5%)。
- 导致停用试验治疗的不良事件:利拉鲁肽组13例(10.4%),安慰剂组0例。
- 严重不良事件:利拉鲁肽组3例(2.4%),安慰剂组5例(4.0%)。
- 利拉鲁肽组发生1例自杀,研究者评估不太可能与试验治疗相关。
临床怎么用
- 对于12至<18岁肥胖且单用生活方式治疗效果不佳的青少年,可考虑利拉鲁肽3.0 mg每日一次联合生活方式治疗。
- 使用期间需关注胃肠道不良事件及因不良事件停药的风险。
- 停药后需监测BMI标准差评分反弹。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity. METHODS: In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents (12 to <18 years of age) with obesity and a poor response to lifestyle therapy alone. Participants were randomly assigned (1:1) to receive either liraglutide (3.0 mg) or placebo subcutaneously once daily, in addition to lifestyle therapy. The primary end point was the change from baseline in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) standard-deviation score at week 56. RESULTS: A total of 125 participants were assigned to the liraglutide group and 126 to the placebo group. Liraglutide was superior to placebo with regard to the change from baseline in the BMI standard-deviation score at week 56 (estimated difference, -0.22; 95% confidence interval [CI], -0.37 to -0.08; P = 0.002). A reduction in BMI of at least 5% was observed in 51 of 113 participants in the liraglutide group and in 20 of 105 participants in the placebo group (estimated percentage, 43.3% vs. 18.7%), and a reduction in BMI of at least 10% was observed in 33 and 9, respectively (estimated percentage, 26.1% vs. 8.1%). A greater reduction was observed with liraglutide than with placebo for BMI (estimated difference, -4.64 percentage points) and for body weight (estimated difference, -4.50 kg [for absolute change] and -5.01 percentage points [for relative change]). After discontinuation, a greater increase in the BMI standard-deviation score was observed with liraglutide than with placebo (estimated difference, 0.15; 95% CI, 0.07 to 0.23). More participants in the liraglutide group than in the placebo group had gastrointestinal adverse events (81 of 125 [64.8%] vs. 46 of 126 [36.5%]) and adverse events that led to discontinuation of the trial treatment (13 [10.4%] vs. 0). Few participants in either group had serious adverse events (3 [2.4%] vs. 5 [4.0%]). One suicide, which occurred in the liraglutide group, was assessed by the investigator as unlikely to be related to the trial treatment. CONCLUSIONS: In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy. (Funded by Novo Nordisk; NN8022-4180 ClinicalTrials.gov number, NCT02918279.).
引用
- Kelly AS, Auerbach P, Barrientos-Perez M, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020. PMID: 32233338. doi:10.1056/NEJMoa1916038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。